Professor Adam Ibrahim Elzagheid, FRCPath (Res) is a distinguished academic pathologist, researcher, and scientific leader with over 25 years of experience in diagnostic pathology, cancer research, and higher education. He currently serves as Director-General of the Libyan Biotechnology Research Center (LBTRC) in Tripoli, Libya, and is Professor of Pathology at the University of Tripoli, as well as Adjunct Professor (Docent) at the University of Turku, Finland.

Professor Elzagheid obtained his PhD in Pathology from the University of Turku, Finland, in 2004, following his M.B.Ch.B from the University of Benghazi in 1996. He subsequently completed postdoctoral training in Oncology and Radiotherapy at Turku University Central Hospital (2004–2007). In recognition of his sustained research excellence, he was awarded Fellowship of the Royal College of Pathologists (FRCPath) by Published Works in 2024.

Over the course of his career, Professor Elzagheid has held numerous senior academic and leadership positions across Libya and Finland. These include Dean of the Faculty of Medicine at the University of Benghazi, Head of multiple academic departments (including Pathology and Microbiology), and leadership roles within the Libyan Authority for Scientific Research. He has also contributed to national scientific governance as a member of the Libyan National Committee for Biosafety and Bioethics, President of the Libyan Pathologists Society.

He has authored more than 95 peer-reviewed publications and abstracts, with over 1,700 citations and an h-index of 23. His work has appeared in high-impact journals such as Nature, The Lancet, Science, Anticancer Research, and World Journal of Gastroenterology. Notable contributions include studies on prognostic biomarkers in colorectal cancer, pharmacogenomics in African populations, multidrug-resistant bacteria, and post-acute COVID-19 pathophysiology.

In addition to his research achievements, Professor Elzagheid has made substantial contributions to medical education and capacity building. He has over two decades of teaching experience across undergraduate and postgraduate levels in pathology, molecular biology, and research methodology. He has supervised and examined numerous postgraduate theses and played a key role in curriculum development, accreditation, and training programs in Libya.

Professor Elzagheid is also an active contributor to the global scientific community, having presented his work at numerous international conferences across Europe, North America, and the Middle East, including the European Congress of Pathology and the International Academy of Pathology. He serves as a reviewer for several international peer-reviewed journals and has been involved in evaluating academic promotions across multiple universities.

As Director-General of LBTRC, he has led major national initiatives to strengthen biotechnology research infrastructure, molecular diagnostics, and translational cancer research in Libya, while fostering international collaborations. His leadership continues to play a pivotal role in advancing scientific research, innovation, and healthcare development in the region.

Molecular Pathology
Tumor Biomarkers
Immunohistochemistry
Cancer Prognostication
Translational Oncology

1. Ramsay^1,48 , I. Alhudiri⁶ , A. Elzagheid⁶ et al. Enriching African genome representation through the AGenDA project, Nature. 2026 Jan;649(8097):565-573. doi: 10.1038/s41586-025-09935-7. IF:48.5 .
2. Inas Alhudiri, Ahmed Abdulmagid Zaghdani, Salah Edin El Meshri, Adel Elmaghrabi, Adam Elzagheid. Libya floods: preventing a public health crisis. The Lancet. 2023 Nov 18;402(10415). (PubMed) IF 88.5 .
3. Nada Elgriw, , Adam Elzagheid et al., Clonal, Plasmidic and Genetic Diversity of Multi-Drug-Resistant Enterobacterales from Hospitalized Patients in Tripoli, Libya. Antibiotics (Basel). 2023 Sep 10;12(9). (PubMed) IF:4.6 .
4. Tegally H, Elzagheid AI, et al. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. Science. 2022 Sep 15. (PubMed) IF: 45.8 .
5. Zakarya Abusrewil, Inas M Alhudiri, et al., Adam Elzagheid. Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays. Journal of Medical Virology 2021 Dec;93(12). (PubMed) IF:4.6 .
6. Elzagheid A, Kuopio T, Ilmen M, Collan Y. Prognostication of invasive ductal breast cancer by quantification of E-cadherin immunostaining: the methodology and clinical relevance. 2002 Aug;41(2):127-33. (PubMed) IF: 4.1 .
7. Elzagheid A et al., E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World Journal of Gastroenterology 2006; 12 (27): 4304-4309. (PubMed) IF:5.4
8. Elzagheid, A., Korkeila, E., Bendardaf, R., Buhmeida, A., Heikkilä, S., Vaheri, A., … & Carpén, O. (2008). Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Human pathology, 39(12), 1737-1743.‏IF:6
9. Alhudiri IM, Nolan CC, Ellis IO, Elzagheid Adam, Rakha EA, Green AR, Chapman CJ. Expression of Lamin A/C in early-stage breast cancer and its prognostic value. Breast Cancer Res Treat. 2019 Apr;174(3). (PubMed) IF:5.6
10. Fetah KL, Elzagheid Adam et al., Cancer Modeling-on-a-Chip with Future Artificial Intelligence Integration. Small. 2019 Dec;15(50). (PubMed) IF:12.0